With 2 Failed Trials, Cyclerion Announces Plans to Cut 30 Out of 135 Jobs

Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day. The company announced topline data from its Phase II proof-of-concept trial of praliciguat in diabetic nephropathy. Praliciguat is a once-daily, oral sGC stimulator. The trial did not meet statistical significance on its primary endpoint of reduction in albuminuria from baseline compared to placebo.